NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG653 Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Briefing

1. Have any potential equality issues been identified during the briefing process (development of the brief or discussion at the committee meeting), and, if so, what are they?

Valve-in-valve surgery was required after TAVI because of valve incompetence or malpositioning in 2% of patients in a register of 1038 patients. (As reported in the overview of IP 685/2: Transcatheter aortic valve implantation for aortic stenosis).

The number of patients undergoing reoperation for valvular heart disease is increasing and will continue to increase as the general population ages. Calcific degenerative aortic valve disease is frequently associated with coronary disease which may be a condition covered by the Disability Discrimination Act (DDA). It also may be part of a congenital heart disease or occur in Turner syndrome (a chromosomal abnormality) in which patients would be covered by the DDA.

Bioprosthetic valves may use materials from either a pig (porcine) or cow (bovine).

No data available from standard IP sources on gender, ethnicity, socioeconomic status, sexual orientation, and gender reassignment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? (If there are exclusions listed in the brief (for example, populations, treatments or settings), are these justified?)

This was not thought to have an impact on the assessment of the procedure. No exclusions were applied. 3. Has any change to the brief (such as additional issues raised during the committee meeting) been agreed to highlight potential equality issues? No 4. Have any additional stakeholders related to potential equality issues been identified during the committee meeting, and, if so, have changes to the stakeholder list been made?' No **Kevin Harris** Approved by Programme Director and Clinical Advisor Date: 02/05/2019 Consultation 1. Have the potential equality issues identified during the briefing process been addressed by the committee, and, if so, how? Not applicable

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the committee addressed these?

No


3.	Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No	
4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligation to promote equality?
Not applicable	
7.	Have the committee's considerations of equality issues been described in the consultation document, and, if so, where?
No	

Kevin Harris

Approved by Programme Director and Clinical Advisor

Date: 02/05/2019

Final interventional procedures document



2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?

No

Mirella Marlow

Approved by Programme Director

Date: 8 May 2019